Question · asked by 1 review
Angiotensin‐converting enzyme inhibitors vs placebo: Serious adverse events
- Population
- people with sickle cell disease
- Intervention
- Angiotensin‐converting enzyme inhibitors
- Comparison
- placebo
- Outcome
- Serious adverse events
The review found no eligible studies for this question.
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Angiotensin‐converting enzyme inhibitors vs placebo Serious adverse events · people with sickle cell disease The review found no eligible studies for this question. Interventions for chronic kidney disease in people with sickle cell disease (2023) · Cochrane Headline outcomes only | no estimate extracted | Not reported | No studies found |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
Related questions
The same intervention and outcome, asked in another population or against another comparator.
- Angiotensin‐converting enzyme inhibitors vs vitamin C · children with sickle cell anaemia and microalbuminuria · 1 review
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.